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Abstract. The peroxisome proliferator-activated receptor γ
(PPARγ) is a nuclear transcription factor that controls the
genes involved in metabolism and carcinogenesis. In the
present study, we examined the alteration of gene expression
in HCT-116 human colorectal cancer cells by PPARγ agonists:
MCC-555 (5 μM), rosiglitazone (5 μM), and 15-deoxy-
Δ12,14-prostaglandin J2 (1 μM). The long-oligo microarray
data revealed a list of target genes commonly induced (307
genes) and repressed (32 genes) by tested PPARγ agonists.
These genes were analyzed by Onto-Express software and
KEGG pathway analysis and revealed that PPARγ agonists
are involved in cell proliferation, focal adhesion, and several
signaling pathways. Eight genes were selected to confirm
the microarray data by RT-PCR and real-time PCR, from
which CSTA, DAP13, TAF12, RIS1, CDKN3 and MAGOH
were up-regulated, and KLHL11 and NCOA2 were down-
regulated. This study elucidates the commonly induced genes
modulated by tested PPARγ ligands involved in the different
signaling pathways and metabolisms, probably mediated in
a PPARγ-dependent manner in colorectal cancer cells and
helps to better understand the pleiotropic actions of PPARγ
ligands.
Introduction
The peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor family and are
activated by agonists that directly bind transcription factors
to regulate the target genes (1). At present, three types of
PPARs have been identified (PPARα, PPARß/δ and PPARγ),
each with different functions, tissue distributions and
activations. Among them, PPARγ is highly expressed in
adipose and colon tissue, and marginally expressed in the
heart, skeletal muscle and liver tissues (2). The PPARγ
activation by agonists regulates adipocyte differentiation and
promotes lipid storage in mature adipocytes. The PPARγ
agonists can also affect cell proliferation, differentiation, and
apoptosis in a PPARγ-dependent and/or independent manner
and thereby represent a potentially important therapeutic
approach to cancer treatments (1). Thus, many studies describe
beneficial effects of the PPARγ agonists for treatment of
different types of cancer (3-7), including colorectal carcinoma
(8,9).
Agonists of PPARγ include prostaglandins of the J series
(PGJ2); the synthetic antidiabetic thiazolidinediones, such
as troglitazone (TGZ), rosiglitazone (RGZ), and MCC-555;
and oxidative metabolites of polyunsaturated fatty acids.
Both TGZ and PGJ2 affect several pathways in a PPARγ-
independent manner: TGZ induces the p53 pathway (10),
inhibits cholesterol biosynthesis (11), inhibits translation
initiation (12), and promotes antioxidant function (13),
whereas PGJ2 induces apoptosis (14) and affects signaling
pathways including Erk1/2 and NF-κB (15). We have also
recently demonstrated that TGZ induces the early growth
response gene (EGR-1) independently of PPARγ transcription
factor activation (8) and that MCC-555 induces apoptosis
in HCT-116 cells, independently of PPARγ (16). Thus, the
anti-cancer activity of the PPARγ agonists should be explored
both dependently and independently at the levels of tran-
scription in several cancer types.
The objective of this study was to investigate the pattern
of genes commonly modulated by three PPARγ agonists
(MCC-555, RGZ and PGJ2) in human HCT-116 colorectal
cancer cells. The long-oligo microarray was employed and
the data revealed a list of target genes commonly induced by
tested PPARγ agonists. The pattern of altered genes was
evaluated by cluster analysis, and the commonly regulated
genes were analyzed by ontology and signaling pathway
analysis, to better understand the biological profiles involved
in PPARγ dependency. In addition, common genes involved
in up-regulation (307 genes) and down-regulation (32 genes)
by PPARγ agonists were analyzed and were shown to play
important roles in cell proliferation, apoptosis, cell adhesion,
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energy homeostasis, insulin metabolism and other signaling
pathways. Eight genes were selected for further analysis,
of which 6 displayed higher mRNA expression in PPARγ
agonist-treated HCT-116 cells than in untreated control:
(DAP13) 13 kDa differentiation-associated protein cystatin A
(CSTA), NADH dehydrogenase 1 α subcomplex 12, 20 kDa
TATA box binding protein (TBP)-associated factor (TAF12),
Ras-induced senescence 1 (RIS1), cyclin-dependent kinase
inhibitor 3 (CDKN3) and mago-nashi homolog (Drosophila)
proliferation-associated (MAGOH). We also determined that
two genes displayed down-regulation of mRNA expression:
kelch-like 11 (KLHL-11) and nuclear receptor coactivator 2
(NCOA2). This study identified several human genes that
were commonly expressed by PPARγ agonists in human
colorectal cancer cells, and this report describes their
possible cellular and physiological roles in PPARγ-dependent
tumor growth.
Materials and methods
Cell lines. Human colorectal adenocarcinoma cell line
HCT-116 was obtained from American Type Culture
Collection (ATCC, Manassas, VA). The cells were maintained
in McCoy's 5A modified medium supplemented with 10%
fetal bovine serum, 100 IU penicillin, and 100 μg/ml strep-
tomycin and grown in an atmosphere of 5% CO2 at 37˚C.
Materials. 5-[[6-[(2-fluorophenyl)-methoxy]-2-napthalenyl]
methyl]-2,4-thiazolidinedione (MCC-555), rosiglitazone
(RGZ) and 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) were
purchased from Cayman Chemical Co. (An Arbor, MI). All
other chemicals and reagents were purchased from Fischer
Scientific, unless otherwise specified.
Plasmids, transient transfections and luciferase assay. The
tk-PPREx3-Luc reporter plasmid, a PPAR-dependent
luciferase construct, was generously provided by Dr Ron
M. Evans (Salk Institute, La Jolla, CA). All transfection
experiments were performed using Lipofectamine reagent
(Invitrogen Corp., Carlsbad, CA) according to the manu-
facturer's instructions. Briefly, HCT-116 cells were seeded
2x105 cells per well in 12-well tissue culture plates in
complete media overnight. Then the cells were co-transfected
with 0.5 μg tk-PPREx3-Luc reporter plasmid and 0.05 μg
pRL-null plasmid. After 5-h transfection, the media were
replaced with complete media overnight, and cells were
treated with different PPARγ agonists (5 μM MCC-555, 5 μM
RGZ, or 1 μM PGJ2) for an additional 24 h. The luciferase
assay was performed using the Dual-Glo luciferase assay
kit (Promega Corp., Madison, WI) according to the manu-
facturer's protocol. Produced luminescence was measured
by a luminometer (TD-20/20, Turner Designs, Sunnyvale,
CA) and data were analyzed by the Student's t-test. The
results at *p<0.05, **p<0.01 and ***p<0.001 were considered
statistically significant.
RNA isolation for microarray analysis. HCT-116 cells were
grown in 100-mm dishes (2x106) in complete media over-
night, and then washed twice with PBS and treated with
5 μM MCC-555, 5 μM RGZ, or 1 μM PGJ2 in serum-free
media for an additional 24 h. Total RNA was isolated from
treated cell samples using an RNeasy mini kit (Qiagen,
Valencia, CA).
Microarray labeling and hybridization. HEEBO long-oligo
microarray slides were purchased from Microarray Inc.
(Nashville, TN) based on a probe set designed by Illumina
(San Diego, http://www.illumina.com) and Stanford
University. The HEEBO long-oligo set contains about
39,000 probes for exonic regions and alternative spliced
transcripts. Total RNA (1 μg) was labeled for each sample
with a SuperScript III Labeling Kit (Invitrogen) according to
the manufacturer's instructions. The purified probes from
both control and treated samples were mixed and hybridized
with the long-oligo microarray using a microarray hybri-
dization kit (Corning, Inc., Corning, NY) on a MAUI
hybridization station (Bio Micro Systems Inc., Salt Lake
City, UT) according to the manufacturer's instruction. Dye
swap experiments were included to eliminate dye-specific
bias. For each sample set of treated vs. control, the treated
mRNA was first labeled with Cy5 and the control with Cy3.
In the reverse experiment, the labeling dyes were swapped.
The two labeling reactions and microarray hybridizations
were performed in parallel. Considering the reverse labeling
experiments, a total of two biological replicates and two
technical replicates of the experiment were performed.
Microarray data processing. After hybridization, the
microarray slides were washed and scanned in a GenePix
4000 scanner (Axon Instrument, Union City, CA), and the
images were processed by GenePix Pro 4.0 software
(Axon Instrument). The resultant file was analyzed with
Bioconductor (http://www.bioconductor.org), where local
background subtraction and lowess normalization were
carried out for each microarray slide. The biological replicates
and technical replicates were considered differently in the
analysis. Linear models from the limma package of
Bioconductor were applied to derive a p-value and average of
logarithm 2-based ratio. Changes in gene expression pattern
were considered statistically significant at *p<0.05. A ratio
cut-off of 1.5 and degree of freedom higher or equal to two
(represents the changes of gene expression on at least three
slide replicates of same experiment) were included as quality
controls. The ratio cut-off of 1.5 in gene expression was
selected because the action of PPARγ agonists are diverse in
gene profiles; so to obtain the list of genes that are commonly
down-regulated, we had to decrease the cut-off to a 1.5-fold
instead of a 2-fold change as is commonly adopted for
microarray data analysis.
In order to evaluate the microarray quality, the M vs. A
plot was generated as a scatter plot of log intensity ratios
M = log2 (R/G) vs. average log intensities A = log2 (RxG)/2,
where R and G represent the fluorescence intensities in the
red (R) and green (G) channels, respectively. Scatter plots
were generated to compare the signal strength between
slides to evaluate the reproducibility of the experiments.
Hierarchical clustering was carried out to cluster among the
genes and among the samples with Mev4.0 software from
TIGR (The Institute of Genome Research). For the gene
ontology analysis and identification of signaling pathways,
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we used Onto-Express software (Onto-Express and Pathway
analysis, Intelligent Systems and Bioinformatics Laboratory,
Detroit, MI).
Reverse transcription PCR. HCT-116 cells were grown in
60-mm dishes (1x106) in complete media overnight, and
then washed twice with PBS and treated with MCC-555 (5,
10 and 50 μM), RGZ (5, 10 and 50 μM), or PGJ2 (1, 2 and
10 μM) in serum-free media for an additional 24 h. Total
RNA was isolated from treated cell samples using an RNeasy
mini kit (Qiagen), and then cDNA was synthesized from
1 μg of total RNA using an iScript cDNA Synthesis kit
(Bio-Rad, Hercules, CA) according to the manufacturer's
protocols. Synthesized cDNA (1 μg) was then added to a
20 μl PCR reaction mixture (GoTaq Green Master Mix
PCR Reaction Mixture, Promega, Madison, WI) with each
set of gene-specific primers. The primer sequences are
described in Table I in detail. The final PCR products were
loaded to agarose gels and photographed under UV light. The
experiments were repeated in three independent replicates.
The densitometries of the captured images were evaluated by
Scion Image Software (Frederick, MD), and were shown on
the final chart with mean ± SE values for each treatment. The
Student's unpaired t-test was used to analyze the statistical
significance.
Quantitative real-time-PCR. Complementary DNA samples
were diluted into 10 ng/μl, 0.1 ng/μl and 0.01 ng/μl concen-
tration series. Three replicates of real-time PCR experiments
were performed for each concentration using an ABI 7000
Sequence Detection System from AB Applied Biosystems
(Foster City, CA) with the ABsolute QPCR SYBR-Green
mix (ABgene House, Epsom, UK). The primers for target
genes were designed by Primer Express software (AB
Applied Biosystems) and the primers sequences are listed in
Table I. The gene for TATA binding protein (TBP) was used
as an internal control. After the real-time PCR experiments,
Ct numbers were extracted for both reference genes and
target genes with auto baseline and manual threshold.
Amplification efficiency for the reactions was estimated as
described previously (17), and multiple regression models
were used to derive point estimation of ΔΔCt, p-value,
standard error and 95% confidence intervals with the SAS
9.1 programs provided (SAS Institute).
Statistical analysis. We used SAS 9.1 (SAS Institute) or
Student's unpaired t-test to analyze the data. Results were
considered statistically significant at *p<0.05, **p<0.01 and
***p<0.001.
Results
Transcriptional activation of the PPARγ receptor by PPARγ
agonists in HCT-116 cells. Agonists of the PPARγ receptor
are known to possess anti-diabetic, anti-inflammatory and
anti-cancer effects. In our study, we used three PPARγ
agonists: two from the synthetic family of thiazolidinediones
(MCC-555 and RGZ), and one naturally occurring metabolite
of arachidonic acid (PGJ2) (Fig. 1A). To confirm that all
three tested compounds are able to activate PPARγ and
transcribe genes containing PPARγ binding sites in HCT-116
cells, a reporter construct, tk-PPREx3-Luc, was transfected
and treated with the indicated PPARγ agonists, and luciferase
activity was measured. It has been reported that HCT-116
cells highly express PPARγ (18). As shown in Fig. 1B,
treatment with 5 μM MCC-555 demonstrates the highest
transcriptional activation of the PPARγ receptor by 4.93-fold
induction (p<0.001) as compared to the other PPARγ
agonists, RGZ and PGJ2 with 2.54- (p<0.001) and 1.37-fold
(p<0.01) inductions, respectively. This result suggests that
HCT-116 cells express functionally active PPARγ proteins
that are responsible for PPARγ agonists.
Transcriptional responses of PPARγ agonists in HCT-116
cells. To examine the transcriptional responses of PPARγ
agonists, gene expression patterns were compared in MCC-
555-, RGZ- and PGJ2-treated HCT-116 cells using long-
oligo microarrays containing the HEEBO oligo set. In our
experiments, the cells were treated with 5 μM MCC-555,
5 μM RGZ and 1 μM PGJ2 for 24 h, and then total RNAs
were isolated and processed for the microarray experiment as
described in Materials and methods. Experiments for each
treatment group were carried out in four replicates. Genes
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Table I. Primer sequences used for RT-PCR.
–––––––––––––––––––––––––––––––––––––––––––––––––
Gene Forward (F) and PCR product
reverse (R) primers size (bp)
–––––––––––––––––––––––––––––––––––––––––––––––––
CSTA F: 5'-ggcttatctgaggccaaacc-3' 217
R: 5'-tttgtccgggaagacttttg-3'
DAP13 F: 5'-gcgaggcaagatggagttag-3' 248
R: 5'-ttccatccacatcccagaat-3'
TAF12 F: 5'-gcaagtctagcaccctggag-3' 201
R: 5'-attgctgtccattccctgac-3'
RIS1 F: 5'-cttccagttccgaaaagcag-3' 165
R: 5'-ttggtcattttctgccatga-3'
CDKN3 F: 5'-catagccagctgctgtgaaa-3' 190
R: 5'-cccggatcctcttaggtctc-3'
SEC61B F: 5'-tgttccagtattggttatgagtcttctg-3' 75
R: 5'-cgagtgtacttgccccaaatg-3'
MAGOH F: 5'-ccaaagaggatgatgcattgtg-3' 77
R: 5'-ttcatctccaatgacgatttcaag-3'
KLHL-11 F: 5'-tcggaaagaagcctaccgatatt-3' 80
R: 5'-ctctacaacgaggttgtggcatag-3'
NCOA2 F: 5'-aatgcatcagcaacagcaag-3' 225
R: 5'-ataagtgggctctggggagt-3'
TBP F: 5'-gcccgaaacgccgaatat-3' 73
R: 5'-ccgtggttcgtggctctct-3'
GAPDH F: 5'-gaccacagtccatgccatcact-3' 560
R: 5'-tccaccaccctgttgctgtag-3'
–––––––––––––––––––––––––––––––––––––––––––––––––
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modulated by PPARγ agonists with statistical significance
between the experimental groups (vehicle vs. treatments)
were identified by SAS statistical software. Changes in gene
expression patterns were considered statistically significant
at p<0.05 if present in at least three replicates (degree of
freedom 2). To evaluate the quality of microarray data, the M
vs. A plot was generated to plot logarithm 2-based two color
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Figure 2. Microarray data quality and analysis. (A) In order to evaluate the hybridization quality of microarrays, the M vs. A plot was generated as a scatter
plot of log intensity ratios M = log2 (R/G) vs. average log intensities A = log2 (RxG)/2, where R and G represent the fluorescence intensities in the red and
green channels, respectively. The M vs. A plot for the normalized average of MCC-555 treatments (4 slides) shows an even distribution of down-regulated
and up-regulated genes across different signal intensities. (B) Hierarchical cluster map of gene expression. The expression matrix displays genes that were
differentially expressed in HCT-116 cells treated by PPARγ agonists. For cluster analysis of the logarithm 2-based gene expression ratio for treatment by
MCC-555, RGZ and PGJ2 (green color down-regulated genes, red color up-regulated genes), we used the following selection criteria: i) at least 1.5-fold
difference between untreated and PPARγ agonist-treated; ii) p-value for difference in expression <0.05 (SAS test); and iii) appearance of the signal in at least
three slide microarray replicates from each treatment. (C) Bend diagrams with the up- and down-regulated genes by MCC-555, RGZ and PGJ2 treatments.
Figure 1. Transcriptional activation of the PPARγ receptor in HCT-116 cells
by PPARγ agonists. (A) Molecular structures of three PPARγ agonists used
in this study, MCC-555 (MCC), rosiglitazone (RGZ) and 15-deoxy-Δ12,14-
prostaglandin J2 (PGJ2). (B) Transcriptional activation of the PPARγ receptor
in HCT-116 cells transfected with tk-PPREx3-Luc reporter plasmid, and
then treated with different PPARγ agonists, MCC-555 (5 μM), RGZ (5 μM)
and PGJ2 (1 μM) for 24 h.
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ratios against the logarithm 2-based two color signal strength
multiples (Fig. 2A), indicating even distribution of down-
regulated and up-regulated genes across different signal
intensities. Scatter plots were also generated to compare the
signal strengths between slides to evaluate the reproducibility
of the experiments and microarray data quality (data not
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Table II. List of commonly 20 up-regulated genes by tested PPARγ ligands, MCC-555, RGZ and PGJ2 (p<0.05, fold change or
ratio >1.5) in HCT-116 cells.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene MCC-555 RGZ PGJ2
–––––––––––––––––––––––––––––––––––––––––––– ––––––––––––––– –––––––––––––––– ––––––––––––––––
Symbol Description p-value Ratio p-value Ratio p-value Ratio
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CSTA Cystatin A (stefin A) 5.73E-05 4.238 5.80E-05 4.18 0.0307297 2.521
UQCRB Ubiquinol-cytochrome c 0.000269 3.079 0.0058807 5.967 0.0019013 4.975
reductase binding protein
COX17 COX17 homolog, cytochrome c 8.76E-05 3.031 0.0049923 5.282 0.0153466 4.09
oxidase assembly protein (yeast)
COX7A2 Cytochrome c oxidase subunit 4.51E-05 3.011 0.0008634 6.178 0.0015228 3.651
VIIa polypeptide 2 (liver)
COMMD6 COMM domain containing 6 0.000369 2.941 0.0013956 8.212 0.0009533 4.718
LOC257039 PREDICTED: similar to 0.000358 2.935 0.0020001 6.81 0.0045161 5.811
ribosomal protein S17
MT1J Metallothionein 1J 4.04E-05 2.917 0.0001288 5.131 0.0204116 2.519
LOC392487 PREDICTED: similar to 0.000151 2.882 0.0055197 5.187 0.0029512 3.77
ribosomal protein L31
LOC130865 PREDICTED: similar to 60S 0.000822 2.837 0.0254389 4.847 0.0091955 4.598
ribosomal protein L26-like 1
LOC391581 PREDICTED: similar to 0.000445 2.835 0.0006942 8.253 0.0072957 3.713
ribosomal protein L31
LOC440539 PREDICTED: similar to 0.000305 2.82 0.0003481 7.013 0.0020661 3.216
ribosomal protein L37
RPL37A Ribosomal protein L37a 0.002622 2.768 9.05E-05 7.718 0.0003969 3.842
LOC343153 PREDICTED: similar to 0.00061 2.761 0.0026409 5.46 0.0063362 2.706
ribosomal protein L26
LOC402318 PREDICTED: similar to 0.00186 2.749 0.0070023 7.32 0.012813 4.682
60S ribosomal protein L32
LOC391035 PREDICTED: similar to 0.003748 2.724 0.0033576 8.008 0.0149866 6.855
ribosomal protein S15a
LOC402716 PREDICTED: similar to 0.000397 2.709 0.0020859 6.651 0.0036407 3.235
60S ribosomal protein L32
RPS21 Ribosomal protein S21 0.00065 2.677 0.0001934 6.545 0.0039326 2.584
LOC346950 PREDICTED: similar to 0.001874 2.648 3.20E-05 8.496 0.0003481 7.725
ribosomal protein L37
COX17 COX17 homolog, cytochrome c 0.000491 2.645 0.0030994 5.341 0.0061663 2.955
oxidase assembly protein (yeast)
NDUFC1 NADH dehydrogenase (ubiquinone) 1, 0.000198 2.635 0.0015227 6.358 0.0032387 3.841
subcomplex unknown, 1, 6 kDa
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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shown). Fig. 2B shows the hierarchical cluster analysis of
the distance between genes regulated by PPARγ agonists.
Interestingly, MCC-555 shows a unique pattern in gene
expression, compared to that of RGZ and PGJ2. This result
may support a previous report that MCC-555 is a dual agonist
for PPARγ and PPARα, whereas RGZ and PGJ2 are PPARγ-
specific agonists (16). As shown in Fig. 2C, microarray data
showed that MCC-555 (5 μM) treatment up-regulated 1056
genes and down-regulated 699 genes, RGZ (5 μM) treatment
up-regulated 6472 genes and down-regulated 6460 genes,
and PGJ2 (1 μM) treatment up-regulated 5105 genes and
down-regulated 5150 genes. Our results demonstrated that
many genes were affected by PPARγ agonists, suggesting
that PPARγ agonists play a role in the regulation of numerous
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Table III. List of commonly 20 down-regulated genes by tested PPARγ ligands, MCC-555, RGZ and PGJ2 (p<0.05, fold
change or ratio <0.667) in HCT-116 cells.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene MCC-555 RGZ PGJ2
––––––––––––––––––––––––––––––––––––––––––––– ––––––––––––––– –––––––––––––––– ––––––––––––––––
Symbol Description p-value Ratio p-value Ratio p-value Ratio
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
FAM13A1 Family with sequence similarity 13, 0.045278 0.399 0.0001102 0.307 0.0062549 0.485
member A1
ARID5B AT rich interactive domain 5B 0.000568 0.428 0.0010759 0.41 0.0407399 0.587
(MRF1-like)
MDM2 Mdm2, transformed 3T3 cell double 0.041641 0.504 0.0001257 0.289 0.0091824 0.44
minute 2, p53 binding protein (mouse)
TEF Thyrotrophic embryonic factor 0.001256 0.527 0.0030892 0.373 0.0211248 0.491
NCOA2 Nuclear receptor coactivator 2 0.011429 0.55 0.0011083 0.228 0.0034108 0.271
FLJ36754 P18SRP protein 0.003659 0.568 0.0029843 0.374 0.0368733 0.599
ATXN1 Ataxin 1 0.009137 0.575 0.0012633 0.367 0.0187268 0.453
KLHL11 Kelch-like 11 (Drosophila) 0.005889 0.581 7.68E-05 0.151 5.34E-05 0.2
D2S448 PREDICTED: melanoma 0.002008 0.589 0.0264569 0.46 0.0218527 0.516
associated gene
ATP9A ATPase, class II, type 9A 0.005898 0.589 0.0050552 0.288 0.0091849 0.384
(ATP9A), mRNA
LOC91664 Similar to zinc finger protein 268, 0.001072 0.591 0.0009028 0.365 0.0435433 0.632
clone IMAGE:3352268
PDE5A Phosphodiesterase 5A, cGMP-specific 0.008455 0.591 0.0002081 0.26 0.000969 0.241
NLN Neurolysin (metallopeptidase M3 family) 0.014697 0.591 0.0013405 0.47 0.0288632 0.606
FLJ10707 PREDICTED: hypothetical 0.010421 0.592 0.0140784 0.257 0.0015614 0.267
protein FLJ10707
APPL Adaptor protein containing pH domain, 0.003269 0.603 0.004938 0.307 0.0048149 0.41
PTB domain and leucine zipper motif 1
ABAT 4-aminobutyrate aminotransferase 0.00488 0.612 0.0073504 0.365 0.0336587 0.5
SCN5A Sodium channel, voltage-gated, type V, 0.002446 0.613 0.0020712 0.442 0.0275364 0.579
α (long QT syndrome 3)
RECQL RecQ protein-like (DNA helicase Q1-like) 0.004036 0.618 0.0004371 0.406 0.0219375 0.536
INPP5D Inositol polyphosphate-5-phosphatase, 0.023678 0.618 0.0039209 0.481 0.0345667 0.607
145 kDa
SUV420H1 Suppressor of variegation 4-20 0.039171 0.624 0.0003402 0.359 0.0221746 0.517
homolog 1 (Drosophila)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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signaling pathways in human colorectal cancer both in a
PPARγ-dependent and independent manner. For further
analysis, we focused on a group of genes commonly regulated
by the tested PPARγ agonists: 307 genes were commonly
up-regulated and 32 genes commonly down-regulated. The
list of top 20 genes commonly altered by PPARγ agonists are
shown in Tables II and III with fold changes (ratios) and
significant p-values. These genes were significantly modulated
by all tested PPARγ agonists, suggesting that alteration of
these genes may act in a PPARγ-dependent manner.
RT-PCR analysis of selected genes modulated by PPARγ
agonists. We have examined the expression of selected
genes by semi-quantitative reverse transcriptase (RT-PCR)
in HCT-116 cells treated by MCC-555, RGZ and PGJ2 for
24 h as described in Materials and methods. We checked
six commonly induced and two commonly repressed genes
from our microarray data, based on the highest induction,
p-value, and potential involvement in tumorigenesis. The six
up-regulated genes are CSTA, DAP13, TAF12, RIS1, CDKN3
and MAGOH. As shown in Fig. 3, results of RT-PCR showed
that the expression levels of these six genes increased in
HCT-116 cells treated with the indicated PPARγ agonists
and consistent with the result of microarray data. In addition,
we selected two down-regulated genes from microarray data
and confirmed their expression by RT-PCR. As shown in
Fig. 4, KLH11 and NCOA2 expression levels were
suppressed by the indicated PPARγ agonists. However, we
did not observe a significant reduction of these two genes in
the presence of RGZ. Since RT-PCR is not sensitive enough
to detect minute differences, we performed real-time PCR to
confirm our microarray data for the down-regulation of gene
expression. The real-time PCR results confirmed down-
regulation of the KLHL-11 and NCOA2 genes (Fig. 4C).
The PCR results are in general consistent with our
microarray data, although RT-PCR results showed smaller
differences than microarray data. Overall, these results
confirmed that CSTA, DAP13, TAF12, RIS1, CDKN3 and
MAGOH are induced by PPARγ agonists, whereas KLHL11
and NCOA2 are down-regulated by PPARγ agonists.
Biological profiles of PPARγ agonist-induced genes. The
final pattern of altered genes was evaluated by cluster
analysis (Fig. 2B), and the commonly regulated genes were
analyzed by ontology and signaling pathway analysis to better
understand the biological phenomena involved in PPARγ
dependency. Functional analysis of genes with a ≥1.5-fold
change in expression (p<0.05 with degree of freedom 2)
was performed using the Onto-Express software to identify
biological process and molecular function categories affected
by PPARγ agonists. The data analysis showed distribution
of biological process (143 genes), molecular function (157
genes), and cellular component classes (144 genes) with
involved genes regulated by PPAR agonists. In addition,
molecular function classes were associated with antioxidant
activity, binding, catalytic activity, enzyme regulator activity,
signal transducer activity, structural molecular activity, tran-
scriptional regulator activity and transporter activity.
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Figure 3. RT-PCR analysis of the selected PPARγ agonist-induced genes in HCT-116 cells. (A) HCT-116 cells were treated by different PPARγ agonists for
24 h as described in Materials and methods in detail. Six up-regulated genes (CSTA, DAP13, TAF12, RIS1, CDKN3 and MAGOH) characterized from our
microarray data were analyzed by RT-PCR. All genes showed increased expression levels by all treatments with MCC-555, RGZ and PGJ2. A housekeeping
gene, GAPDH, was used for internal control and normalization. (B) Charts of the densitometry analysis of represented genes. Each chart represents
the mean value ± SE of three independent experiments.
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Furthermore, the functional importance of PPARγ-induced
target genes was analyzed by Pathway Express Software and
reflected in major KEGG pathways containing previously
well-identified and established genes. As shown in Fig. 5
the pathways affected by PPARγ agonists were cell cycle
(CHEK2, MDM2 and RBX1), cytokine-cytokine receptor
interaction (IL18 and VEGFB), ubiquitin-mediated proteo-
lysis (UBE2E1 and RBX1), phosphatidylinositol signaling
system (INPP5D), insulin signaling pathway (INPP5D),
Wnt signaling pathway (RBX1), TGF-ß signaling pathway
(RBX1), focal adhesion (VEGFB), calcium signaling pathway
(SLC25A4) and colorectal cancer pathway (APPL).
Discussion
Colorectal cancer is the third most common cancer and
the third leading cause of cancer-related mortality in the
United States according to the American Cancer Society.
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Figure 4. RT-PCR analysis of the selected PPARγ agonist-repressed genes in HCT-116 cells. (A) HCT-116 cells were treated by different PPARγ agonists for
24 h as described in Materials and methods in detail. Two down-regulated genes (KLHL11 and NCOA2) characterized from our microarray data were
analyzed by reverse transcriptase-PCR. Genes showed repressed expression levels by treatments with MCC-555, RGZ and PGJ2. (B) Charts of the
densitometry analysis of represented genes. Each chart represents the mean values ± SE of three independent experiments. (C) Real-time PCR analysis
of the down-regulated genes in HCT-116 cells treated with MCC-555 (5 μM), RGZ (5 μM) and PGJ2 (1 μM) for 24 h. Charts represent the mean values ± SE
of three independent experiments with three dilutions.
Figure 5. Scheme of pleiotropic action of PPARγ on various signaling pathways in human HCT-116 colorectal cancer cells.
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However, over the past decade, colorectal cancer incidence
and mortality rates have decreased compared to other cancers,
and it is believed that chemoprevention research on human
colorectal cancer has significantly contributed to this reduced
risk. It is well known that the use of non-steroidal anti-
inflammatory drugs (NSAIDs) decreases the risk of colorectal
cancer and is very effective for chemoprevention. Data from
our and other laboratories indicate that PPARγ agonists
also induce apoptosis and have anti-tumorigenic effects in
colorectal cancer (8,9). PPARγ agonists play a pivotal role in
anti-tumorigenesis in a PPARγ-dependent and -independent
manner (1), and that is why both pathways should be
considered to investigate their roles. In this regard, our data
may provide an up-to-date list of genes on which PPARγ
agonists act in a PPARγ-dependent and -independent manner
in human colorectal cancer cells. In our experiments, we
used the HEEBO long-oligo set which contains about
39,000 probes for exonic regions, and the alternative spliced
transcripts microarray screening technique to identify the
genes and signaling pathways commonly regulated by three
different PPARγ agonists in human HCT-116 colorectal
adenocarcinoma cells. As shown in this study, the expression
of several genes was modulated either positively (307) or
negatively (32) by three PPARγ agonists in HCT-116 cells,
suggesting that both activation and repression can play an
important role of PPARγ agonists in tumorigenesis, cell
growth and differentiation. MCC-555 treatment showed a
unique pattern of gene expression with the least number of
modified genes compared to the RGZ or PGJ2 treatments
(Fig. 2B and C). One possible explanation is that MCC-555
also binds to PPARα and possesses distinct properties
compared to other PPARγ agonists. Indeed, we have shown
that MCC-555 increases tumor suppressor protein NAG-1 at
the post-transctiptional level, whereas TGZ affects it at the
transcriptional level (16).
We have identified some of the genes that are growth-
related, or involved in tumor invasion, metastasis and
apoptosis. Cystatin A or stefin A (CSTA) has been known to
belong to family I of cysteine proteinase inhibitors, which are
commonly down-regulated in many cancers. A large body of
literature has accumulated to suggest that stefins correlate
with malignancy of various murine and human tumors (19),
such as lung, gastric, brain, colorectal and malignant mela-
noma (20). Cystatins act as tumor suppressor genes and
positively relate with survival probability (21). Our data
showed that the CSTA gene was up-regulated by all tested
PPARγ agonists, which can have a beneficial effect on the
treatment of colorectal cancer. Another tumor-growth related
gene, CDKN3, which belongs to the dual specificity protein
phosphatase family, was identified as a cyclin-dependent
kinase (Cdk) inhibitor. CDKN3 has been shown to interact
with the dephosphorylated Cdk-2 kinase, and thus prevent
its activation (22). Our data indicate that all tested PPARγ
agonists induced the expression of the CDKN3 gene, which
may be a potential candidate for a colorectal cancer target
gene to inhibit cell cycle progression.
Unlike the above-mentioned genes CSTA and CDKN3,
MAGOH, TAF12, RIS1 and DAP13 genes are potentially
new candidate genes associated with cancer. MAGOH is
one of the eight PPARγ-regulated genes reported in this
study, and its protein product is the human homolog of the
Drosophila mago-nashi protein (23). Magoh protein plays
important roles in mRNA splicing functions in the nucleus and
cytoplasm. Indeed, both null mutation in flies and disruption
of mRNA by RNAi in C. elegans show embryonic lethality,
indicating that magoh is essential for viability (24). In our
study, the expression of the MAGOH gene was up-regulated
in human HCT-116 colorectal cancer cells; however, its exact
biological function and regulation by PPARγ agonists in
colorectal cancer remains to be elucidated. In contrast, little is
known about DAP13 [also known as NADH dehydrogenase
(ubiquinone) 1 α subcomplex 12, NDUFA12], except that
it is described as a theoretical product of a gene identified
in a lung adenocarcinoma cell line that had been induced
to differentiate by treatment with all trans-retinoic acid (25).
Colorectal tumors develop mostly through several
pathways, which are characterized by mutations in several
suppressor genes (APC, SMAD and TP53) and oncogenes
(KRAS2, MYC) and in chromosome instability. Ras-induced
senescence 1 (RIS1) is a novel gene identified by Barradas
et al (26), and is up-regulated in association with Ras sene-
scence. The RIS1 gene is located at chromosomal position
3p21.3, previously defined for its tumor-suppressor activity
(27); this region frequently exhibits the loss of heterozygosity
in tumors, which is what confers this gene a putative role as
a tumor suppressor. Moreover, mutations in the RIS1 gene
are associated with a worse prognosis and development of
metastasis in colorectal tumors (28). Another gene regulated
by PPARγ agonists is TAF12 RNA polymerase II, a TATA
box binding protein (TBP)-associated factor, which is an
important part of the protein complex controlling the tran-
scription by RNA polymerase II, and controlling the cell cycle
and apoptosis (29). It has been shown that TAF12 interacts
with ATF7, a transcription factor, and that this interaction
can be modulated by another TAF protein, TAF4 (30).
Other genes characterized in our study are KLHL11
and NCOA2 that are down-regulated by PPARγ agonists.
KLHL11 is the human ortholog of the identified zebrafish
gene, kelchlike (klhl), an important gene involved in embryo-
genesis. The human KLHL gene is specifically expressed
in the muscles and heart, which suggests a role in muscle
cytoarchitecture (31). Our microarray data also showed the
down-regulation of nuclear receptor co-activator 2 gene,
NCOA2, which is a family member of p160 kDa proteins
involved in regulation of nuclear receptors, such as estrogen
receptors and androgen receptors (32). It has been reported
that NCOA2 and other cofactors including SRC-1, p300/
CBP, and Tip60 are up-regulated in advanced prostate cancer
(32), suggesting that suppression of its expression is beneficial
to prostate and other cancers.
Co-activators and co-repressors modulate the activity of
PPARγ with influence on tumor formation. The pattern of
commonly PPARγ agonist-altered genes were analyzed using
the Onto-Express software, and signaling pathway analysis
by Pathway Express Software was done to reflect the major
KEGG pathways to better understand the biological
phenomena involved in PPARγ dependency (Fig. 5).
However, KEGG pathway analyses were not able to
recognize the new genes involved in well established
signaling pathways. Microarray data and ontology report
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analysis showed that PPARγ plays an important role in
cellular processes, development, growth, physiological
processes, regulation of biological process, response to
stimulus, antioxidant activity, binding, catalytic activity,
enzyme regulator activity, signal transducer activity, structural
molecular activity, transcriptional regulator activity and
transporter activity.
A better understanding of the PPARγ receptor and its
molecular signaling pathway opens up new therapeutic
prospects in treatment of colorectal cancer. Our microarray
data of PPARγ-induced genes showed that PPARγ agonists
induced pleiotropic effects on the transcriptional program of
human colorectal adenocarcinoma cells, involving metabolic
(e.g., amino acid and lipid metabolism) and hormonal (e.g.,
sterol biosynthesis), cell organization, and regulatory path-
ways (e.g., cytoskeletal proteins). This raises the possibility
that these additional mechanisms might contribute to the
anti-cancer activity of nuclear receptor agonists, perhaps in
a tumor-specific and tissue-specific manner. From all of
the above, it is clear that the influence of PPARγ on cell
cycle proliferation, differentiation and apoptosis is complex.
These effects depend on the concentrations of agonists, the
cell type, and/or the mutational events that predispose cancer
development. The full understanding of the mechanisms
requires additional laboratory studies to address the role of
PPARγ in tumorigenesis.
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